Pharmaceutical Compositions

A combination therapy modulates dysfunctional neural processes by reactivating and stabilizing neural circuits to reduce symptoms of psychostimulant use disorders, levodopa-induced dyskinesia, and post-traumatic stress disorder, enhancing treatment efficacy and compliance.

JP7594045B2Active Publication Date: 2024-12-03DUKE UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023085969
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2015-01-28
Filing Date
2023-10-11
Publication Date
2024-12-03
Estimated Expiration
2036-01-28

AI Technical Summary

Technical Problem

Current treatments for psychostimulant use disorders, levodopa-induced dyskinesia, and post-traumatic stress disorder have limited efficacy and require strict compliance due to side effects and reactivation of dysfunctional neural circuits, necessitating supervised environments for administration.

Method used

A combination therapy that temporarily modulates dysfunctional neural processes by reactivating neural circuits with a first component and stabilizing them with a second component, administered at a specific time delay to block reconsolidation, reducing symptoms to subclinical levels.

Benefits of technology

The therapy effectively reduces symptoms of psychostimulant use disorders, levodopa-induced dyskinesia, and post-traumatic stress disorder by normalizing neural function and improving patient compliance through convenient dosing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594045000003
    Figure 0007594045000003
  • Figure 0007594045000004
    Figure 0007594045000004
  • Figure 0007594045000005
    Figure 0007594045000005
Patent Text Reader

Abstract

To provide a composition and method for combination therapy capable of temporarily regulating inherent dysfunctional neural processes and reducing symptoms and / or signs of neuropsychiatric disorders.SOLUTION: A pharmaceutical composition for treating neuropsychiatric disorders is provided comprising a component 1, which comprises a DA (dopamine) agonist or a pharmaceutically acceptable salt thereof, and a component 2, which comprises an antagonist or inverse-agonist of a 5-HT2A / 2C receptor subtype or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: Figure 2
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] U.S. Federal Government Funding and Entitlements

[0002] This invention was made in part with funding from the U.S. Federal Government under NIH-approved grants R01 DA012768 entitled "Cocaine Withdrawal: A Window of Treatment Opportunity"; R01 DA14323 entitled "Drug Development for Methamphetamine Abuse"; NS42124 entitled "Presynaptic Mechanisms and Treatment of Parkinson's Disease"; and RC2 DA028905 entitled "Novel Ondansetron Formulations for the Combination Treatment of Psychostimulant Abuse." Accordingly, the Federal Government may have certain rights in this invention.

[0003] Priority claim

[0004] This application claims priority to U.S. Provisional Application No. 62 / 108,616, filed January 28, 2015, which is incorporated by reference in its entirety for all purposes.

[0005] Technical Field

[0006] The present invention relates to combination therapeutic compositions and methods that can temporarily modulate underlying dysfunctional neural processes and reduce the symptoms and / or signs of neuropsychiatric disorders, including, but not limited to, psychostimulant use disorder (PUD) and substance-related and addictive disorders, post-traumatic stress disorder (PTSD) and trauma-and stressor-related disorders, and levodopa-induced dyskinesia (LID) and other forms of dyskinesia. [Background technology]

[0007] Any disorder described in the present invention is described based on the criteria described in the Diagnostic and Statistical Manual of Mental Disorders Version 5 (DSM-5), the International Statistical Classification of Diseases and Related Health Problems version 10 (ICD-10), or both. The contents described in the present invention will be easily understood by a person of ordinary skill in the art.

[0008] Although numerous therapeutic approaches have been developed for the treatment of neuropsychiatric disorders, solutions to their side effects are likewise sought.

[0009] Let's look at some examples of neuropsychiatric disorders.

[0010] Psychostimulant Use Disorder (PUD)

[0011] Misuse of cocaine (COC), methamphetamine (METH) and related drugs (collectively referred to as "psychostimulants") continues to impose legal, socio-economic and medical costs worldwide, not only as a primary psychiatric disorder, but also as a significant comorbidity / risk factor in a variety of other neuropsychiatric and medical conditions, such as schizophrenia, bipolar disorder, hepatitis C and HIV (Whiteford et.al., 2013). (Whiteford, HA, Degenhardt, L, Rehm,J, Baxter, AJ, Ferrari,AJ, Erskine,HE,Charison,FJ, Norman,RE, Flaxman, AD, Johns, N, Burstein, R, Murray, CJL, Vos, T (2013). Global burden of diseases attributable to Mental and substance use disorders: findings from the Global Burden of Diseases Study 2010. The Lancet 382:1575-1586).

[0012] Despite the high unmet medical need for effective treatments for psychostimulant use disorder (PUD), over 20 drugs in clinical trials have shown limited efficacy, and none have been approved by the FDA for this indication. Currently, medications used to treat PUD patients are typically limited to treating comorbid psychiatric conditions. Additionally, a number of psychotropic medications have been used off-label to treat psychostimulant dependence, but their effectiveness has not been rigorously tested. Drugs that have been tested in previous clinical trials include other psychostimulants used alone (e.g., d-amphetamine, methylphenidate), selective dopamine (DA) or serotonin uptake inhibitors (e.g., fluoxetine), full or partial DA agonists (e.g., aripiprazole), DA antagonists (e.g., risperidone), GABA (gamma-aminobutyric acid) agonists (e.g., gabapentin), and the central nervous system stimulant modafinil. Additional medications (e.g., bupropion, n-acetylcysteine, the antiepileptic drugs tiagabine and topiramate) and other treatment approaches (e.g., anti-cocaine and anti-METH vaccines or transcranial magnetic stimulation) continue to be evaluated clinically (Haile et.al., 2012 (Haile, CN, Mahoney, JJ, 3rd, Newton, TF, De La Garza, R, 2nd (2012)).(See Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate, Pharmacol Ther 134:260-277.) Common patterns of treatment outcomes in such clinical trials are: (1) treatments that show promise in small trials fail to prove effective in larger trials (e.g., vigabatrin); or (2) efficacy only in certain subgroups of patients (e.g., modafinil and topiramate are effective only in patients without alcohol use disorder, and disulfiram is effective only in patients with certain genotypes and only in one-third of patients who received an anti-cocaine vaccine with a valid antibody response). Thus, there remains a high unmet need within the medical community for drugs that can be used effectively and sustainably to treat psychostimulant use disorders with the goal of reducing illicit psychostimulant use.

[0013] Unlike suboptimal treatment outcomes in human clinical trials or medical practice, select combinations of DA agonists and 5HT2, 5-HT3 or NK-1 receptor antagonists can reverse the behavioral and neurobiological alterations observed in sensitization and self-administration animal models of PUD. Thus, as reviewed in a recent paper by Lee et al., 2012 (Lee, TH, Szabo, ST, Fowler, JC, Mannelli, P, Mangum, OB, Beyer, WF, Patkar, A, Wetsel, WC(2012). Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy. Drug and alcohol dependence 124:11-18), such treatments (1) reverse established COC or METH behavioral hypersensitivity; (2) reduce the rate of progression and self-administration in drug-induced reinstatement paradigms; and (3) normalize the changes in relevant neurobiological indices. Key findings from this study include: (1) consistent therapeutic effects were achieved in animal models only when the antagonist was administered 3.5 hours or later, but not before or together with the agonist; (2) one-day DA agonists or 5-HT antagonists administered alone were ineffective.

[0014] Although combination treatment methods in which 5HT2, 5-HT3 or NK-1 receptor antagonists are administered to animals after a fixed delay of 3.5 hours following administration of a DA agonist have been well established in animal PUD models (see Lee et al., 2012, supra), in practice, to obtain any therapeutic effect similar to this in clinical practice, it is limited by the fact that it must rely entirely on a dosing schedule that forces patients to take the two drugs at the individual prescribed times (i.e., 3.5 hours after administration of the agonist, the antagonist must be administered). Because patients diagnosed with a primary or comorbid psychiatric disorder are typically unwilling or unable to adhere to prescribed treatment regimens, the application of such treatments to reduce illicit drug use in patients with PUD and other psychiatric disorders is likely to fail in the absence of clinical practice-level measures to ensure treatment compliance. Thus, the successful use of combination treatments in such patients typically requires a monitored environment, such as an inpatient or residential treatment facility.

[0015] Levodopa-induced dyskinesia (LID)

[0016] For patients diagnosed with Parkinson's disease and / or other related disorders (PD), DA replacement therapy is used to restore DA neurotransmission in the brain and alleviate the symptoms and signs of PD and other related disorders. The dopamine (DA) prodrug levodopa (L-3,4-dihydroxyphenylalanine) is one of the most effective drugs for alleviating PD motor signs and symptoms. However, its use has limited utility in the long-term management of PD patients due to its tendency to induce side effects, namely levodopa-induced dyskinesia (LID) and associated loss of efficacy. Furthermore, even with the "optimal" levodopa therapy, up to 90% of Parkinson's disease patients develop LID within 5 to 10 years. This makes LID one of the major causes of failure of levodopa therapy (with or without supplemental dopamine agonists) in PD patients.

[0017] Levodopa sensitization and LID

[0018] Among all the mechanisms, levodopa sensitization plays an important role in the development and maintenance of LID. Dysregulation of DA synthesis, extracellular DA release and clearance due to progressive DA neuronal death and / or "ectopic" DA synthesis and release at 5-HT terminals is believed to cause excessive fluctuations in synaptic DA concentrations after levodopa administration. Such fluctuations in turn induce abnormalities in the basal ganglia and other brain regions and synaptic changes.

[0019] Based on the putative role of fluctuating synaptic DA levels, several therapeutic strategies designed to maintain consistent levodopa levels have been utilized to block the development of LID or to counter the onset of levodopa sensitivity through the induction of tolerance. These strategies include (1) the use of controlled- or extended-release levodopa formulations or "round-the-clock" levodopa administration therapy; (2) the addition of catechol-o-methyltransferase inhibitors to reduce synaptic DA concentration fluctuations; (3) intraduodenal levodopa injection; and (4) levodopa patches. Unfortunately, these "continuous" levodopa access methods have not been as effective as originally hoped. Reasons for such less-than-optimal efficacy may include, but are not limited to, (1) decreased maximum levodopa concentrations (relative to a given "equivalent" dose); (2) development of pharmacokinetic tolerance; and (3) the emergence of novel and distinct neurobiological changes during extended "sustained" levodopa treatment, a phenomenon that has been well documented with direct and indirect DA agonists. It is also important to note that while maintaining DA agonist levels up to 12 to 14 hours per day still induces behavioral sensitization, longer drug concentrations (e.g., 18 hours or more per day) induce tolerance (Ellinwood et al., 2002 (Ellinwood, EH, Davidson, C, Yu, GZ, King, GR, Lee, TH (2002). Effect of Daily dosing duration of direct and indirect dopamine receptor agonists: cocaine cross-tolerance following chronic regimens. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 12:407-415)).It has been suggested that maintaining drug concentrations within the effective therapeutic range for extended periods of time often results in increased occurrence of nocturnal side effects such as nightmares, sleep disorders, etc. In light of these considerations, it has been proposed that a number of factors, including individual differences in drug metabolism, the ability of patients to adhere to prescribed dosing regimens, and / or non-compliance due to increased LID or other side effects, may cause variability in the duration of constant levodopa levels, thereby limiting the use of "long-acting" therapies as an "anti-LID" strategy.

[0020] Other "anti-LID" strategies proposed alongside "long-acting" levodopa therapy include the use of alternative drugs to levodopa or the coadministration of levodopa and "anti-LID drugs" to prevent LID development or block existing LID expression. Many other therapeutic agents or candidates in all stages of development are currently being evaluated. Recently, deep brain stimulation (DBS) has been on the rise, despite its invasive properties and the risk of long- and short-term post-treatment complications, but it is not yet systematically clear whether such treatments directly alter the neurobiological changes at the core of LID or whether they have an indirect effect, such as by reducing the dose of levodopa, secondary blocking of LID expression and / or slowing the rate of PD progression.

[0021] Post-traumatic stress disorder (PTSD)

[0022] In the United States, the National Comorbidity Survey Replication (NCS-R) estimated the 12-month (annual) prevalence of PTSD in adults to be 3.5%. Of these, 36.6% were considered severe. Overall, the lifetime prevalence of PTSD in the United States is estimated to be 8-9%, with an associated cost of approximately $8 billion, and it is twice as likely to occur in women as in men. The 12-month prevalence rate is 1.8% in men and 5.2% in women (National Institute of Mental Health, 2010), and the prevalence rate in adolescents (ages 13-18) is approximately 4%. Due to this high prevalence, 49.9% of the population in the United States seeks voluntary treatment each year, and of these, 42% receive minimally adequate treatment.

[0023] In South Korea, according to Korean National Health Insurance statistics, the total number of PTSD patients (outpatients and inpatients) was 6,981 in 2014, 6,741 in 2013, and 6,950 in 2012. When analyzing the total number of patients by gender, the number of male patients is 1.5 times higher than the number of female patients. When analyzing by age group between 10 and 60 years old, there is a relatively uniform number of patients across all age groups.

[0024] Treatment options currently known to have "meaningful" or "some" benefits in the "Pocket Guide to Post-Traumatic Stress Disorder" 2013 (Pocket Guide) include psychological treatments (e.g., "cognitive" and "exposure" treatments) and pharmacological treatments. In the case of pharmacological treatments, antidepressants, especially selective serotonin or serotonin / norepinephrine reuptake inhibitors, have shown efficacy in randomized controlled trials; among these, only sertraline and paroxetine have been approved by the US Food and Drug Administration (FDA) for the treatment of PTSD. Benzodiazepines, atypical antipsychotics, and anticonvulsants have also been considered, but these drugs have not shown consistent efficacy and are not included in the list of drugs recommended in the aforementioned guidelines. On the other hand, the combination of exposure therapy and paroxetine has been reported to have no additional therapeutic effect compared to exposure therapy. Currently, clinical trials are continuing to evaluate additional treatments and investigational new drugs (INDs) either as monotherapy or as an expansion strategy to existing forms of PTSD treatment.

[0025] Neural basis of neuropsychiatric disorders

[0026] Various neuropsychiatric disorders, including PUD, LID, and PTSD, are considered to be enhanced forms of maladaptive dysfunctional neural circuits ("dysfunctional neural plasticity" or "dysfunctional memory"). Disorder-specific neuroplasticity is altered at many levels, including but not limited to neural mechanisms and processors, brain regions, connectivity between brain regions, brain networks, and intra- and extra-brain network interactions, which are believed to underlie the signs and symptoms of a particular disorder (see Headley and Pare, 2013 (Headley, DB, Pare, D (2013). In sync: gamma oscillations and emotional memory. front Behav Neuroschi7: 170)). Therefore, it can be said that treatment-mediated normalization of such neuroplastic changes can bring about successful treatment outcomes.

[0027] Figure 1 shows the mechanisms underlying the maintenance of dysfunctional neural circuits.

[0028] For example, in patients diagnosed with PUD, as shown in Figure 1, the stably strengthened "PUD neural circuitry" can be reactivated by exposure to a number of stimuli, such as psychostimulants themselves (e.g., "low-drug tasting"), environmental cues associated with drug use (e.g., drug paraphernalia), or "stress" (Childress et al., 1999 (Childress, Ar, Mozley, PD, McGin, W, Fitzgerald, J, Reivich, M, O'brien, CP (1999). Limbic activation during cue-induced cocaine craving. The American journal of psychiatry 156: 11-18); Shinha, 2006 (Shinha, R, Garcia, M, Paliwal, P, Kreek, MJ, Rounsaville, BJ (2006). Stress-induced cocaine craving and (Hypothalamic-pituitary-adrenal responses are predictive of cocaine relapes outcomes. Archives of general psychiatry 63: 324-331; see Lee et al., 2012, supra). Unless interfered with, reactivated memories undergo reconsolidation during withdrawal, as seen in the "crash" symptoms experienced during withdrawal.

[0029] LID is another form of reconsolidation of “dysfunctional neuroplastic changes” that is maintained by repeated reactivation with therapeutic administration of levodopa and subsequent reconsolidation during which the therapeutic effect of levodopa is diminished pharmacokinetically (PK) and / or pharmacodynamically (PD).

[0030] In a similar manner to dysfunctional PUD or LID neural circuits, the dysfunctional "PTSD neural circuits" of PTSD patients can be conceptualized as being maintained through repeated reactivation and reconsolidation cycles. For example, if a patient is exposed to a previously traumatic stressful event (e.g., a noise that reminds one of a bomb explosion that killed a friend, getting into a car after a major car accident, etc.), the dysfunctional neural circuits can be reactivated. Such reactivation can cause the re-emergence of PTSD signs and symptoms, which can be calmed down if the reactivated PTSD circuit is reconsolidated to a state where it is stable and can be easily reactivated. Reconsolidation weakens the PTSD symptoms and signs, making them susceptible to re-emergence with the next encounter with the stimulus. [Detailed Description of the Invention] Summary of the Invention [Problem to be solved by the invention]

[0031] The present invention aims to provide combination therapy compositions and methods that can temporarily modulate underlying dysfunctional neural processes to reduce the symptoms and / or signs of neuropsychiatric disorders, including, but not limited to, psychostimulant use disorder (PUD) and other substance-related addictive disorders, post-traumatic stress disorder (PTSD) and other trauma- and stress-related disorders, and levodopa-induced dyskinesia (LID) and other forms of movement disorders. [Means for solving the problem]

[0032] Based on the above conceptualization, the present invention provides a method in which the agents used in the combination method therapeutically reactivate a stable dysfunctional neural circuit in its "reactivated and unstable" state, thereby temporarily rendering it unstable, whereby an antagonist given at an appropriate time following administration of the agents temporarily modulates the underlying dysfunctional neural process by blocking reconsolidation and subsequent circuit restabilization, thereby in turn reactivating and blocking the reconsolidation of maladaptive memories, such that the symptoms and / or signs of the neuropsychiatric disorder may be progressively reduced to subclinical levels, thereby providing a composition and method of combination therapy that can reduce the symptoms and / or signs of neuropsychiatric disorders, including but not limited to psychostimulant use disorder (PUD) and other substance-related addictive disorders, post-traumatic stress disorder (PTSD) and other trauma- and stress-related disorders, and levodopa-induced dyskinesia (LID) and other forms of movement disorders. Effect of the Invention

[0033] In accordance with the present invention, compositions and methods of combination therapy are provided that can temporarily modulate underlying dysfunctional neural processes to reduce symptoms and / or signs of neuropsychiatric disorders, including, but not limited to, psychostimulant use disorder (PUD) and other substance-related addictive disorders, post-traumatic stress disorder (PTSD) and other trauma- and stress-related disorders, and levodopa-induced dyskinesia (LID) and other forms of movement disorders, and further include (1) other substance-related disorders, including, but not limited to, tobacco use disorder, alcohol use disorder, and cannabis use disorder; (2) behavioral addiction disorders, including, but not limited to, gambling addiction and internet addiction; (3) other trauma and stressor-related disorders, including, but not limited to, reactive attachment disorders, acute stress disorder, and adjustment disorder; (4) anxiety disorders, including, but not limited to, generalized anxiety disorders, panic disorder, agoraphobia, substance / drug-induced anxiety disorder; (5) obsessive-compulsive disorder, body dysmorphic disorder, and other disorders. (5) obsessive-compulsive disorders, including but not limited to, dysmorphic disorders, hoarding disorders, trichotillomania, and excoriation disorders; and (6) other neuropsychiatric disorders, including but not limited to, eating disorders, including but not limited to, anorexia nervosa, bulimia, and binge eating disorder. [Brief description of the drawings]

[0034] [Figure 1] FIG. 1 shows the mechanism of maintenance of dysfunctional neural circuits.

[0035] [Diagram 2] FIG. 2 is a diagram showing the mechanism of combination therapy according to the present invention.

[0036] [Diagram 3]FIG. 3 is a graph showing that the combination of the DA agonist pergolide and the 5-HT2A / 2C antagonist ketanserin significantly reduces levodopa-induced abnormal involuntary movements (LIAIM) from rats, an animal model of LID. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0037] [Best Mode for Carrying Out the Invention] Below are detailed descriptions of compositions and methods, and illustrative examples illustrating the principles of the invention. The examples are provided to illustrate aspects of the invention, but the invention is not limited to any specific examples. The scope of the invention includes various alternatives, modifications, and equivalents; it is limited only by the scope of the claims.

[0038] It should be readily apparent to those skilled in the art that the present invention can be successfully adapted to carry out the objects and obtain the ends and advantages mentioned as well as those inherent therein. The detailed description set forth herein is provided as representative of the presently preferred embodiments and is exemplary and is not intended to limit the scope of the present invention. Those skilled in the art to which the present invention pertains can make modifications thereto and other applications within the spirit of the invention as defined by the scope of the appended claims.

[0039] Numerous specific details are set forth below for a thorough understanding of the present invention. However, the present invention may be practiced according to the claims without some or all of these specific details. For the sake of clarity, technical materials known in the art related to the present invention will not be described in detail so as not to unnecessarily obscure the invention.

[0040] Any disorder described within the present invention is described by the criteria described in the Diagnostic and Statistical Manual of Mental Disorders Version 5 (DSM-5), the International Statistical Classification of Diseasess and Related Health Problems Version 10 (ICD-10), or both. Also, the target indications described within the present invention can belong to the primary diagnosis (n) or secondary diagnosis (n) or side effects or comorbid conditions.

[0041] As explained in the Background of the Invention, various neuropsychiatric disorders, including but not limited to PUD, LID and PTSD, can be conceptualized as a stable and strengthened form of dysfunctional maladaptive synaptic plasticity, which is maintained through repeated reactivation / reconsolidation cycles. Although pharmacological options are currently available for many neuropsychiatric disorders, the majority of such treatments are "temporary" insofar as they primarily alleviate the signs and symptoms of the targeted primary and / or comorbid disorder. There remains a high unmet need for more effective pharmacological treatments that can normalize ("diseases modification") the underlying dysfunctional neural circuits.

[0042] FIG. 2 is a diagram showing a conceptual model of combination therapy according to the present invention.

[0043] In the novel combination therapy as shown in FIG. 2, the first component (component 1) is used in a single embodiment to reactivate the dysfunctional neural circuit in a stable reactivated state, temporarily creating an unstable state for the dysfunctional neural circuit. In the same embodiment, the second component (component 2), provided in any embodiment or single composition, dosage form or administration form together with the first component, blocks the reconsolidation and subsequent restabilization process in a stable state. Thus, such a composition or dosage form, optimized in combination therapy aspect and at the same time convenient for the patient, serves to repeatedly reactivate the dysfunctional memory and prevent reconsolidation so that the symptoms and signs of the target disorder are gradually reduced to subclinical (subclinical) levels and normal neural function is restored (e.g., successful treatment). The compositions, methods and embodiments described within the present invention allow for the effective clinical application of such combination therapy as a single administration form.

[0044] The combination therapy embodiments described herein, which include two active components, can be used to treat neuropsychiatric disorders. Disorders that can be treated with the combination therapy embodiments include PUD, LID, and PTSD. Other disorders include, but are not limited to: (1) other substance-related disorders, including but not limited to tobacco use disorder, alcohol use disorder, and cannabis use disorder; (2) behavioral addiction disorders, including but not limited to compulsive gambling and Internet addiction; (3) other trauma and stressor-related disorders, including but not limited to reactive attachment disorders, acute stress disorder, and adjustment disorder; (4) anxiety disorders, including but not limited to generalized anxiety disorder, panic disorder, agoraphobia, and substance / drug-induced anxiety disorder; (5) obsessive-compulsive disorders, including but not limited to obsessive-compulsive disorder, body dysmorphic disorder, hoarding disorders, trichotillomania, and excoriation disorders; and (6) eating disorders, including but not limited to anorexia nervosa, bulimia, and binge eating disorder.

[0045] Although distinct symptoms, signs, specific brain circuits, and other diagnostic criteria distinguish such disorders, they share a common attribute of enhanced forms of dysfunctional neuroplasticity that also involve one or more of the same neurotransmitters, receptors, molecules, and signaling pathways, such as dopamine, glutamate, brain-derived neurotrophic factor (BNDF), dopamine receptor subtypes, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA), N-methyl-D-aspartate (NMDA), and metabotropic glutamate 5 (mGluR5) glutamate receptors, and numerous protein kinases and pseudokinases, in the formation, strengthening, and / or maintenance of these distinct dysfunctional neurocircuits. Accordingly, such disorders may be amenable to therapeutic intervention with the combination therapies described herein.

[0046] The combination therapy can be carried out in any embodiment, dosage form, method, or route that can be understood in the art and compatible with the clinical application being carried out. Component 1 provides a means to change the maladaptive dysfunctional neural circuit from a stable state to a reactivated state, thereby temporarily imparting instability to the maladaptive dysfunctional neural circuit. Component 2, included in any embodiment or single composition, dosage form, or dosage form together with component 1, blocks reconsolidation and subsequent restabilization to a stable state. Thus, such any embodiment or single composition, dosage form, or dosage form optimizes the combination therapy and allows the components to be delivered to the body in a form and manner that is convenient for the patient, thus reducing the signs and symptoms of the targeted disorder to subclinical levels. The compositions, dosage forms, methods, and exemplary embodiments described herein allow for the effective use of the combination therapy as a single dosage form.

[0047] 1, component 1 may be selected from small molecules, other forms of molecules and their variants (e.g., pharmaceuticals, prodrugs, etc.). Other forms of molecules include, but are not limited to, small interfering ribonucleic acid (siRNA), microRNA, antisense oligonucleotides, aptamers, peptides, proteins (e.g., antibodies), naturally occurring organic or inorganic molecules, chemical elements (e.g., lithium), and any synthetic compound larger or smaller than a small molecule, which can be delivered via any safe, acceptable and effective route of administration and preferably contained in a single combination therapeutic dosage form to achieve abnormal neural circuit reactivation, in which the abnormal neural circuit is transferred from a stable state to a reactivated and unstable state.

[0048] 2. In one combination therapy embodiment, component 1 is a pharmacologically-effective indirect or direct DA agonist, or a pharma- ceutically acceptable salt thereof, with or without norepinephrine (NE) and / or serotonin (5-HT) agonistic efficacy. If a direct DA agonist is selected, the agonist may or may not exhibit a preference for D1-type or D2-type DA receptors. Importantly, unless otherwise specified, the terms "D1" and "D1-type" are used interchangeably herein to refer to one or both of the D1 and D5 receptors. Similarly, "D2" and "D2-type" are used interchangeably to refer to the D2, D3, and D4 DA receptors, respectively, and any of the above. When stereoisomers of the selected component 1 exist, any stereoisomer alone or combinations thereof in their respective optimized ratios may be used. Component 1 may also be any of the substances described in 1 above and variations thereof, which are expected to be functional DA agonists based on (1) their known physiochemical properties, as assessed by any analytical method known to those of skill in the art, including, but not limited to, pharmacophore-based "docking," virtual computational screening, and other in vitro / in silico analytical methods; and / or (2) their in vitro and / or in vivo pharmacological profiles.

[0049] 2.1. If an indirect DA agonist is selected for component 1 (e.g., a DA prodrug, a DA releasing agent, or a DA reuptake inhibitor), then pharmacologically active and / or 5-HT antagonists (e.g., d-amphetamine, methylphenidate, selective dopamine norepinephrine reuptake inhibitors) are preferred over indirect DA agonists that are not pharmacologically active NE and / or 5-HT antagonists (e.g., selective DA reuptake inhibitors).

[0050] 2.2. When a direct DA agonist is selected as component 1, non-selective D1-type and D2-type DA receptor agonists are preferred over D1-selective or D2-selective receptor agonists.

[0051] 2.3. If a direct DA agonist is selected as component 1, then agents that act as pharmacologically effective NE and / or 5-HT agonists are preferred over those without NE and / or 5-HT potency, etc.

[0052] 2.4. Agents and pharma- ceutically acceptable salts thereof and any variations thereof that exhibit immediate and pulsatile release profiles in in vitro and / or in vivo tests known to those skilled in the art (e.g., in vitro dissolution tests, evaluation of in vivo pharmacokinetic parameters) are preferred over any other combinations / permutations that exhibit immediate, delayed, or pulsatile, extended / sustained release profiles. One preferred in vitro agent release profile is 90% or greater dissolution within 2 hours under gastric or intestinal in vitro dissolution test conditions, with a more preferred profile being 80% or greater dissolution within 1 hour under the same test conditions.

[0053] 2.5. The agent and its pharma- ceutically acceptable salts and modifications (including any one or all of the active metabolites) may have a terminal elimination half-life (t1 / 2) in the human body of 20 hours or less. A suitable terminal elimination half-life (t1 / 2) is 10 hours or less, and a more suitable terminal elimination half-life (t1 / 2) is 5 hours or less.

[0054] 3. Component 2 can be selected from small molecules, other forms of molecules and modifications thereof (e.g., pharmaceuticals, prodrugs, etc.). Other forms of molecules include, but are not limited to, small interfering ribonucleic acids, microRNAs, antisense oligonucleotides, aptamers, peptides, proteins (e.g., antibodies), naturally occurring organic or inorganic molecules, chemical elements (e.g., lithium), and any synthetic compound larger or smaller than a small molecule, which can be preferably delivered through any safe, acceptable and effective route of administration and contained within a single combination therapeutic dosage form for blocking the re-strengthening of dysfunctional neural circuits, whereby dysfunctional neural circuits are reactivated and transitioned from an unstable state to a stable state.

[0055] 4. In one embodiment, component 2 is a selective or non-selective receptor antagonist or inverse agonist of the 5-HT2 receptor, a selective or non-selective receptor antagonist or inverse agonist of the 5-HT3 receptor, a selective or non-selective antagonist or inverse agonist of the NK-1 receptor, including 5-HT2, 5-HT3 and NK-1 receptor subtypes, single-nucleotide polymorphisms and other transcriptional, translational and post-translational modifications of the respective receptors expressed in humans. Specific examples of this include, but are not limited to, ketanserin and its chemical isomers (e.g., mianserin); mirtazapine and its chemical isomers (e.g., setiptiline); ondansetron, granisetron, dolasetron, palonosetron and tropisetron.

[0056] When stereoisomers of the selected component 2 exist, any stereoisomer alone or combinations thereof in optimized proportions of each can be used.

[0057] Component 2 may also be any of the substances described in 3 above and variations thereof, which are expected to be (1) functional antagonists of 5-HT2, 5-HT3 and / or NK-1 agonists based on their known physiochemical properties, as assessed by any analytical method known to those of skill in the art, including, but not limited to, pharmacophore-based "linking", virtual computational searches and other in vitro / in silico analytical methods; and / or (2) functional antagonists of 5-HT2, 5-HT3 and / or NK-1 agonists based on in vitro and / or in vivo pharmacological profiles.

[0058] 4.1. When a 5-HT2 antagonist or inverse agonist is selected for component 2, an antagonist or inverse agonist that prefers the 5-HT2A subtype alone, the 5-HT2C subtype alone, or all 5-HT2A and 5-HT2C subtypes is preferred over other 5-HT2 antagonists or inverse agonists that prefer a different 5-HT2 subtype.

[0059] 4.2. If a pharmacologically effective 5-HT3 antagonist or inverse agonist is selected as component 2, the antagonist or agonist may or may not exhibit the physiochemical, in vitro and in vivo pharmacological properties and / or profile expected of an antagonist, inverse agonist or full or partial agonist from the alpha 7 (α7) nicotinic receptor. A selective 5-HT3 antagonist is more preferred than a 5-HT3 antagonist per se or than would be expected of a pharmacologically effective alpha 7 nicotinic antagonist, inverse agonist or full or partial agonist.

[0060] 4.3. When a pharmacologically active NK-1 antagonist or inverse agonist is selected as component 2, the antagonist or inverse agonist may or may not be selective for the NK-1 receptor subtype relative to the NK-2 and / or NK-3 receptor subtypes, however, a non-selective NK-1 antagonist is preferred over a selective NK-1 antagonist.

[0061] 4.4. Antagonists and pharmaceutically acceptable salts thereof and any variants thereof that exhibit delayed and pulsatile release profiles in in vitro and / or in vivo tests known to those skilled in the art (e.g., in vitro dissolution tests, in vivo determination of pharmacokinetic parameters) are preferred over any other combinations / permutations that exhibit immediate, delayed, or pulsatile, extended / sustained release profiles. One preferred in vitro release profile of the antagonist is 10% dissolution in 3 hours or more to 80% dissolution in 7 hours or less under gastric or intestinal in vitro dissolution test conditions.

[0062] 4.5. The antagonist and its pharma- ceutically acceptable salts and variants (including any one or all of the active metabolites) may have an elimination half-life (t1 / 2) of 20 hours or less in the human body, with a suitable elimination half-life (t1 / 2) of 16 hours or less, a more suitable elimination half-life (t1 / 2) of 14 hours or less, and a more preferred elimination half-life (t1 / 2) range of 3 to 13 hours.

[0063] 5. The maximum drug concentration upon in vivo administration is defined as "Cmax" and the time at which Cmax is reached is defined as "Tmax". The difference between the Tmax of the pharmacologically active form of component 1 and the Tmax of the pharmacologically active form of component 2 plays an essential role in determining the efficacy of the combination therapy. For all therapeutic indications described herein, the Tmax separation between the plasma or serum concentrations of the pharmacologically active forms of component 1 and component 2 in humans may range from 1 to 12 hours. A suitable range is 1 to 8 hours, with a more suitable separation being 2 to 8 hours. More preferably, it is 2 to 7 hours.

[0064] 6. The Tmax of component 1 and / or component 2 can be modified through a number of methods, including but not limited to: (1) the use of pharmacologically inactive prodrugs, including but not limited to those which effect activation in the gastrointestinal tract, blood, liver or other organs; or (2) dosage form-based modification of a pharmacologically active parent form. Many dosage form-based modifications can be used to achieve targeted in vivo pharmacokinetic profiles in humans, including but not limited to pH-based, osmolarity-based, and liposome-based modification methods.

[0065] 7. The composition for combination therapy may be embodied in any dosage form, including, but not limited to, tablets, capsules, solutions, gels, suspensions, films, patches, and suppositories. The dosage form may be a pharmaceutical composition, which contains the active ingredients as component 1 and component 2, and may further contain pharma- ceutically acceptable additives such as excipients and carriers for formulation, and any additives that are pharma- ceutically acceptable and can aid in formulation, such as shaping, and aid in ingestion, may be used. For example, the active ingredient may be contained in a predetermined amount as a powder, or in granules, in a solution, or in an aqueous or non-aqueous liquid, in a suspension, in an oil-in-water emulsion, or in a water-in-oil liquid emulsion. Each dosage form may be prepared by any pharmaceutical method, but all methods include a step of associating the active ingredient with a carrier composed of one or more essential ingredients. In general, the composition is prepared by uniformly and finely mixing the active ingredient with a liquid carrier or a fractional solid carrier, or both, and then, if necessary, shaping the product into the desired form. For example, the composition may be prepared by compressing or molding, optionally with one or more accessory ingredients. Compressed compositions may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with excipients, such as, but not limited to, binders, lubricants, inert diluents, and / or surfactants or dispersants. Molded compositions may be prepared by molding in a suitable machine a mixture of the powdered compound with an inert liquid diluent.

[0066] The present invention further includes anhydrous pharmaceutical compositions and dosage forms containing active ingredients, since water can promote the decomposition of some compounds. For example, water can be added in pharmaceutical applications as a means of simulating long-term storage to determine characteristics such as the shelf life or stability of a formulation. Anhydrous pharmaceutical compositions and dosage forms of the present invention can be prepared using anhydrous or low moisture content ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms of the present invention containing lactose can be prepared anhydrous if substantial contact with moisture and / or humidity is expected during manufacture, packaging, and / or storage. Anhydrous pharmaceutical compositions can be prepared and stored to maintain their anhydrous nature. Thus, anhydrous compositions can be packaged using materials known to prevent exposure to water so that they can be included in suitable prescription kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers, fountain packs, and strip packs.

[0067] The active ingredient can be formulated into a combination mixture with a pharmaceutical carrier by conventional pharmaceutical compounding techniques. The carrier can take a variety of forms depending on the dosage form suitable for administration. In formulating compositions for oral dosage forms, any conventional pharmaceutical medium can be used, such as carriers such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, etc., for oral liquid dosage forms (e.g., suspensions, solutions, and elixirs) or aerosols; or carriers such as starch, sugars, microcrystalline cellulose, diluents, granules, lubricants, binders, and disintegrants can be used for oral solid dosage forms, in some embodiments not utilizing lactose. For example, suitable carriers include powders, capsules, and preparations with solid oral dosage forms. If necessary, preparations can be coated by standard aqueous or nonaqueous techniques.

[0068] Binders suitable for use in pharmaceutical compositions and dosage forms include, by way of non-limiting example, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, calcium carboxymethylcellulose, sodium carboxymethylcellulose), polyvinylpyrrolidone, methylcellulose, pregelatinized starch, hydroxypropyl methylcellulose, microcrystalline cellulose, and mixtures thereof.

[0069] Examples of fillers suitable for use in the pharmaceutical compositions and dosage forms disclosed herein include, by way of non-limiting example, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, gelatinized starch, and mixtures thereof.

[0070] Disintegrants can be used in the compositions of the present invention to provide compositions that disintegrate when exposed to an aqueous environment. Too much disintegrant can produce compositions that can disintegrate in an unhealthy manner. Too little can cause insufficient disintegration, and the rate and extent of release of the active ingredient(s) from the dosage form can be altered. Thus, dosage forms of the compounds disclosed herein can be formed using a sufficient amount of disintegrant, but not too little, so that the release of the active ingredient(s) is adversely altered. The amount of disintegrant used can vary according to the formulation type and mode of administration, and can be readily identified by one of ordinary skill in the art. About 0.5 to about 15% by weight of disintegrant, or about 1 to about 5% by weight of disintegrant can be used in the pharmaceutical composition. Disintegrants that can be used to form pharmaceutical compositions and dosage forms of the present invention include, by way of non-limiting example, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polarcrylline potassium, sodium starch glycolate, potato or tapioca starch, other starches, gelatinized starches, other starches, clays, other algins, other celluloses, gums or mixtures thereof.

[0071] Lubricants that can be used in forming pharmaceutical compositions and dosage forms of the invention include, by way of non-limiting example, calcium stearate, magnesium stearate, mineral oil, white mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oils (e.g., peanut oil, cotton oil, sunflower seed oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laurate, agar, or mixtures thereof.

[0072] Additional lubricants include, for example, syloid silica gel, a coagulated aerosol of synthetic silica, or mixtures thereof. A lubricant can optionally be added in an amount of less than about 1% by weight of the pharmaceutical composition.

[0073] When aqueous suspensions and / or elixirs are suitable for oral administration, the essential active ingredients thereof may be combined with various sweeteners or flavorings, coloring substances or dyes, and, where appropriate, emulsifying and / or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, and various mixtures thereof.

[0074] The preparation can be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract, providing a sustained action over a long period of time. For example, a time-delay material such as glyceryl monostearate or glyceryl distearate can be used. The dosage form for oral use can also be in a hard gelatin capsule, in which the active ingredient is mixed with an inert solid diluent, such as calcium carbonate, calcium phosphate or kaolin, or in a soft gelatin capsule, in which the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil. The preparation can be disintegrated to allow for rapid release of the therapeutic agent.

[0075] Surfactants that can be used to form the pharmaceutical compositions and dosage forms of the present invention include, by way of non-limiting example, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof, i.e., a mixture of hydrophilic surfactants can be used, a mixture of lipophilic surfactants can be used, or a mixture of one or more hydrophilic surfactants and one or more lipophilic surfactants can be used.

[0076] A proper hydrophilic surfactant can usually have an HLB value of 10 or more, while a proper lipophilic surfactant can usually have an HLB value of about 10 or less. The empirical variable used to characterize the relative hydrophilicity and hydrophobicity of nonionic amphiphilic compounds is the hydrophilic-lipophilic balance ("HLB" value). Surfactants with lower HLB values ​​are more lipophilic or hydrophobic and have higher solubility in oils, whereas surfactants with higher HLB values ​​are more hydrophilic and have higher solubility in aqueous solutions. Hydrophilic surfactants are usually considered compounds with HLB values ​​greater than about 10, as well as anionic, cationic, or zwitterionic compounds for which the HLB scale is generally not applicable. Similarly, lipophilic (i.e., hydrophobic) surfactants are compounds with HLB values ​​of about 10 or less.

[0077] However, the HLB value of a surfactant is merely a rough guideline that is commonly used in formulating industrial, pharmaceutical and cosmetic emulsions.

[0078] The hydrophilic surfactant may be ionic or non-ionic. Suitable ionic surfactants include, but are not limited to, alkyl ammonium salts, fusidate salts, fatty acid derivatives of amino acids, oligopeptides and polypeptides, glyceride derivatives of amino acids, oligopeptides and polypeptides, lecithin and hydrogenated lecithin, lysolecithin and hydrogenated lysolecithin, phospholipids and derivatives thereof, lysophospholipids and derivatives thereof, carnitine fatty acid ester salts, alkyl sulfate salts, fatty acid salts, sodium docusate, acyl lactylates, monoacetylated and diacetylated tartaric acid esters of monoglycerides and diglycerides, succinylated monoglycerides and diglycerides, citric acid esters of monoglycerides and diglycerides, and mixtures thereof.

[0079] Within the aforementioned group, examples of preferred ionic surfactants include lecithin, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; alkyl sulfates; fatty acid salts; sodium toxate; acyl lactylates; monoacetylated and diacetylated tartaric acid esters of mono- and diglycerides; succinylated mono- and diglycerides; citric acid esters of mono- and diglycerides; and mixtures thereof.

[0080] Ionic surfactants include lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP-phosphatidylethanolamine, lactyl esters of fatty acids, stearoyl-2-lactylate, stearoyl lacty ... The ionized forms of the glyceryl esters may be glyceryl esters, succinylated monoglycerides, mono / diacetylated tartaric acid esters of mono / diglycerides, citrate esters of mono / diglycerides, cholyl sarcosine, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenic acid, stearate, lauryl sulfur, teraceyl sulfur, docusate, lauroyl carnitine, palmitoyl carnitine, myristoyl carnitine and salts and mixtures thereof.

[0081] Hydrophilic nonionic surfactants include, but are not limited to, alkyl glycosides; alkyl maltosides; alkyl thioglycosides; lauryl macrogol glycerides; polyoxyalkylene alkyl ethers, such as polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols, such as polyethylene glycol alkylphenols; polyoxyalkylene alkylphenol fatty acid esters, such as polyethylene glycol fatty acid monoesters and polyethylene glycol fatty acid diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fatty acid esters, such as polyethylene glycol sorbitan fatty acid esters; hydrophilic transesterification products of polyols and one or more members of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; polyoxyethylene sterols, derivatives, and analogs thereof; polyoxyethylated vitamins and derivatives thereof; polyoxyethylene-polyoxypropylene block copolymers; and mixtures thereof; hydrophilic transesterification products of polyethylene glycol sorbitan fatty acid esters and polyols and one or more members of the group consisting of triglycerides, vegetable oils, and hydrogenated vegetable oils. The polyol may be glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, or a polysaccharide.

[0082] Other hydrophilic nonionic surfactants include, but are not limited to, PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-40 stearate, PEG-50 stearate, PEG-60 stearate, PEG-70 stearate, PEG-80 stearate, PEG-90 stearate, PEG-100 stearate, PEG-110 stearate, PEG-120 stearate, PEG-130 stearate, PEG-140 stearate, PEG-150 stearate, PEG-160 stearate, PEG-170 stearate, PEG-180 stearate, PEG-190 stearate, PEG-200 stearate, PEG-200 stearate, PEG-200 stearate, PEG-200 stearate, PEG-32 distearate, PEG-400 stearate, PEG-150 stearate, PEG-32 distearate, PEG-400 stearate, PEG-150 stearate, PEG-160 stearate, PEG-170 stearate, PEG-180 stearate, PEG-200 stearate, PEG-200 stearate, PEG-200 stearate, PEG-200 stearate, PEG- Alate, PEG-100 Stearate, PEG-20 Dilaurate, PEG-25 Glyceryl Trioleate, PEG-32 Dioleate, PEG-20 Glyceryl Laurate, PEG-30 Glyceryl Laurate, PEG-20 Glyceryl Stearate, PEG-20 Glyceryl Oleate, PEG-30 Glyceryl Oleate, PEG-30 Glyceryl Laurate, PEG-40 Glyceryl Laurate, PEG-40 Panconelle Oil, PEG-50 Hydrogenated Pisumer Oil, PEG -40 pizama oil, PEG-35 pizama oil, PEG-60 pizama oil, PEG-40 hydrogenated pizama oil, PEG-60 hydrogenated pizama oil, PEG-60 corn oil, PEG-6 caprate / caprylate glyceride, PEG-8 caprate / caprylate glyceride, polyglyceryl-10 laurate, PEG-30 cholesterol, PEG-25 phytosterol, PEG-30 soy sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 These include sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopheryl PEG-100 succinate, PEG-24 cholesterol, polyglyceryl-10 oleate, Tween 40, Tween 60, Zadan monostearate, Zadan monolaurate, Zadan monopalmitate, PEG 10-100 nonylphenol series, PEG 15-100 octylphenol series and poloxamer.

[0083] Examples of suitable lipophilic surfactants include fatty acid alcohols, glycerol fatty acid esters, acetylated glycerol fatty acid esters, lower alcohol fatty acid esters, propylene glycol fatty acid esters, sorbitan fatty acid esters, polyethylene glycol sorbitan fatty acid esters, sterols and sterol derivatives, polyoxyethylated sterols and sterol derivatives, polyethylene glycol alkyl ethers, sugar esters, sugar ethers, lactic acid derivatives of monoglycerides and diglycerides, hydrophobic transesterification products of one or more members of the group consisting of polyols and glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids and sterols, oil-soluble vitamins / vitamin derivatives, and mixtures thereof. Within the above group, preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters and mixtures thereof, or hydrophobic transesterification products of one or more members of the group consisting of polyols and vegetable oils, hydrogenated vegetable oils and triglycerides.

[0084] In one embodiment, the composition may include a solubilizer that provides good solubility of the active ingredient and minimizes precipitation. This may be particularly important for compositions for parenteral use, such as injectable compositions. Solubilizers may also be added to increase the solubility of hydrophilic drugs and / or other ingredients, such as surfactants, and to maintain the composition as a stable or homogeneous solution or dispersion. Examples of suitable solubilizers include, but are not limited to, alcohols and polyols, such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediol and its isomers, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethylisosorbide, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, hydroxypropylmethylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; ethers of polyethylene glycol having an average molecular weight of about 200 to about 6000, such as tetrahydrofurfuryl alcohol PEG ether (glycofurol) or methoxy PEG; amides and other nitrogen-containing compounds, such as 2-pyrrolidone, 2-piperidone, epsilon, cyclodextrins, cyclodextrin derivatives ... -caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide and polyvinylpyrrolidone; esters such as ethyl prothionate, tributyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, triethyl citrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, ε-caprolactone and its isomers, δ-valerolactone and its isomers, β-butyrolactone and its isomers; and other solubilizing agents known in the art such as dimethylacetamide, dimethylisosorbide, N-methylpyrrolidone, monooctanoin, diethylene glycol monoethyl ether and water.

[0085] Mixtures of solubilizers can also be used.Non-limiting examples include triacetin, triethyl citrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrin, ethanol, polyethylene glycol 200-100, glycopyrrol, transcutol, propylene glycol, and dimethyl isosorbide.Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycopyrrol, and propylene glycol.

[0086] The amount of solubilizer that can be included is not particularly limited. The amount of solubilizer can be limited to a biologically acceptable amount, which can be easily measured by a person skilled in the art. In some circumstances, it may be advantageous to include an amount of solubilizer that does not exceed a biologically acceptable amount, in other words, to maximize the concentration of the drug, and excess solubilizer is removed using conventional techniques, i.e., distillation or evaporation, before providing the composition to the patient. Thus, when present, the solubilizer may be in a weight ratio of 10%, 25%, 50%, 100%, or up to about 200% by weight based on the combined weight of the drug and other excipients. If necessary, very small amounts of solubilizer, i.e., 5%, 2%, 1% or less, may also be used. Typically, the solubilizer may be present in an amount of about 1% to about 100%, more commonly about 5% to about 25% by weight.

[0087] The composition may further comprise one or more pharma- ceutically acceptable additives and excipients, including, by way of non-limiting example, adhesion reducers, antifoaming agents, buffers, polymers, antioxidants, preservatives, chelating agents, viscosity modifiers, tonicity agents, flavors, colorants, odorants, opacifying agents, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof.

[0088] Acids or bases can also be incorporated into the compositions to facilitate processing, improve safety, or for other reasons. Examples of pharma- ceutically acceptable bases include amino acids, amino acid esters, ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium bicarbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrotalcite, magnesium aluminum hydroxide, disopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, triethylamine, trisopropanolamine, trimethylamine, tris(hydroxymethyl)aminomethane (TRIS), and the like. Also suitable are bases that are salts of pharma- ceutically acceptable acids, such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carboxylic acids, citric acid, fatty acids, formic acid, pumaric acid, gluconic acid, hydroquinonesulfonic acid, isoascorbic acid, lactic acid, maleic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, and the like. Salts of polyprotic acids, such as sodium phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate, may also be used. When the base is a salt, the cation may be any conventional pharma-ceutically acceptable cation, i.e., ammonium, alkali metals, alkaline earth metals, and the like. Non-limiting examples include sodium, potassium, lithium, magnesium, calcium, and ammonium.

[0089] Suitable acids include pharma- ceutically acceptable organic or inorganic acids. Examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, boric acid, phosphoric acid, and the like. Examples of suitable organic acids include acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carboxylic acid, citric acid, fatty acids, formic acid, pumaric acid, gluconic acid, hydroquinonesulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, and the like.

[0090] In some embodiments of the injectable pharmaceutical composition, the present invention provides an injectable pharmaceutical composition comprising component 1 and component 2 as active ingredients, particularly a formulation that reduces or eliminates the side effects of component 1. In some embodiments, the present invention provides an injectable pharmaceutical composition comprising a formulation that reduces or eliminates the side effects of component 1 and a combination of pharmaceutical excipients suitable for injection. The ingredients and amounts of the formulations in the composition are as described herein.

[0091] Forms in which the novel compositions of the present invention can be introduced for administration by injection include aqueous or oily suspensions, or emulsions, sesame oil, corn oil, cotton oil, or peanut oil, and elixirs, mannitol, dextrose, or sterile aqueous solutions and similar pharmaceutical vehicles.

[0092] In saline, aqueous solutions are also commonly used for injection. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be used. Proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Prevention of the action of microorganisms can be prevented by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.

[0093] Sterile injectable solutions are prepared by incorporating the active ingredient in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients in a sterile vehicle containing a basic dispersion medium and the other ingredients as required from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred preparation method is vacuum drying and freeze-drying techniques, which form a powder of the active ingredient and any additional desired ingredients from a previously sterile-filtered solution thereof.

[0094] The composition of the present invention can be formulated in solid, semi-solid, or liquid form suitable for topical or local administration, such as gel, water-soluble jelly, cream, lotion, suspension, foam, powder, slurry, ointment, solution, oil, paste, suppository, spray, emulsion, saline solution, dimethyl sulfoxide (DMSO)-based solution. Generally, dense carriers can provide the active ingredient to the part exposed for a long period of time. In contrast, solution formulations can further provide the active ingredient to the selected part for immediate exposure.

[0095] The pharmaceutical composition may also include suitable solid or gel carriers or excipients, which are compounds capable of increasing the permeability of therapeutic molecules or facilitating the delivery of said molecules across the stratum corneum permeability barrier of the skin. There are numerous permeation enhancing molecules known to have been cultivated in the topical formulation field. Non-limiting examples of said carriers and excipients include humectants (e.g., urea), glycols (e.g., propylene glycol), alcohols (e.g., ethanol), fatty acids (e.g., oleic acid), surfactants (e.g., isopropyl myristate and sodium lauryl sulfate), pyrrolidone, glycerol monolaurate, sulfoxides, terpenes (e.g., menthol), amines, amides, alkanes, alkanols, water, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers, such as polyethylene glycol.

[0096] Another dosage form that can be used in the methods of the present invention uses a transdermal delivery device (e.g., a patch or a minipump). The transdermal device can be used to provide continuous or discontinuous infusion of the active ingredient in controlled amounts. Thus, in some embodiments, the present invention provides a transdermal device for the introduction of the agonist and / or antagonist.

[0097] The construction and use of transdermal devices for the delivery of pharmaceutical agents are known in the art. See, e.g., U.S. Patent Nos. 5,023,252, 4,992,445, and 5,001,139. ​​Such devices can be constructed for continuous, pulsatile, or on-demand delivery of pharmaceutical agents.

[0098] Pharmaceutical compositions for inhalation, compositions for inhalation or ingestion include solutions and suspensions in pharma- ceutically acceptable aqueous or organic solvents, or mixtures thereof, and pharma- ceutically acceptable powders. The liquid or solid compositions may contain suitable pharma- ceutically acceptable excipients as described above. Preferably, the compositions are administered via the oral or nasal respiratory route for local or systemic effect. Preferably, in a pharma- ceutically acceptable solvent, the compositions can be nebulized using an inert gas. The nebulized solutions can be inhaled directly from the nebulizer or the nebulizer can be attached to a face mask tent, or intermittent positive pressure respirator. Solution, suspension, or powder compositions can be administered, preferably orally or intranasally, from a means that delivers the dosage form in any suitable manner.

[0099] Other pharmaceutical compositions may be prepared from the compositions described herein and pharma- ceutical acceptable excipients suitable for sublingual, buccal, rectal, intramedullary, ocular, nasal, epidural, or intraspinal administration. The preparation of such pharmaceutical compositions is well known in the art. For example, see the literature [Anderson,philip O.;Knoben, James E.;Troutman, William G, eds., Handbook of Clinical Drug Data, Tenth Edition, McGraw-Hill, 2002; Pratt and Taylor, eds., Principles of Drug Action, Third Edition, Churchill Livingston, New York, 1990;Katzung, ed., Basic and Clinical Pharmacology, Ninth Edition, McGraw Hill, 20037ybg; Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, Tenth Edition, McGraw Hill, 2001; Remingtons Pharmaceutical Sciences, 20th Ed., Lippincott Williams & Wilkins., 2000; Martindale, The Extra Pharmacopoeia, Thirty-Second Edition (The Pharmaceutical Press, London, 1999); all of the above references are incorporated herein by reference in their entireties.

[0100] 8. The combination therapy dosage form may be administered through any route and method, including, but not limited to, oral, intravenous, intranasal, inhalation (e.g., dose-metered intrapulmonary), sublingual, transdermal, subcutaneous, and intracerebral routes.

[0101] 9. Neuropsychiatric disorders that may be treated with combination therapy include PUD, LTD, and PTSD. In addition to PUD, LTD, and PTSD, indications include, but are not limited to: (1) other substance-related disorders, including but not limited to tobacco use disorder, alcohol use disorder, and cannabis use disorder; (2) behavioral addiction disorders, including but not limited to gambling and internet addiction; (3) other trauma- and stress-related disorders, including but not limited to reactive attachment disorder, acute stress disorder, and adjustment disorder; (4) anxiety disorders, including but not limited to generalized anxiety disorder, panic disorder, agoraphobia, substance / drug-induced anxiety disorder; (5) obsessive-compulsive disorders, including but not limited to obsessive-compulsive disorder, body dysmorphic disorder, hoarding disorder, trichotillomania, and excoriation disorder; and (6) eating disorders, including but not limited to anorexia nervosa, bulimia, and binge eating disorder.

[0102] 10. The combination dosage form may be used with other treatments and dosage forms to provide an additive or enhancer effect compared to the effect of the combination dosage form given alone. Examples of treatments or dosage forms that may be used with the combination therapy include, but are not limited to, behavioral therapies such as cognitive behavioral therapy, extinction therapy, and exposure therapy, and pharmacological treatments using anti-epileptics, antipsychotics, antidepressants, and ketamine.

[0103] 11. To the extent that many symptoms and signs of such disorders are frequently observed in patients with other primary neuropsychiatric diagnoses as comorbid disorders, secondary symptoms / signs and / or side effects of treatment for such disorders, combination treatments can be used as supplemental, additive, ameliorative and / or preventative adjunctive treatments.

[0104] 12. In one preferred combination dosage form, component 1 is any unmodified or any other immediate-release dosage form of methylphenidate, and component 2 is any delayed, pulsatile-release dosage form of ondansetron. Any combination / permutation of methylphenidate and ondansetron dosages can be used. The preferred dosage range for methylphenidate in the dosage form is 0.1 to 80 mg equivalent of unmodified methylphenidate hydrochloride, and the preferred dosage range for ondansetron dosage form is 0.1 to 32 mg equivalent of unmodified ondansetron hydrochloride. The more preferred dosage range for methylphenidate in the dosage form is 1 to 80 mg equivalent of unmodified methylphenidate hydrochloride, and the more preferred dosage range for ondansetron dosage form is 1 to 16 mg equivalent of unmodified ondansetron hydrochloride. A more preferred dosage range for methylphenidate in the dosage form is 5 to 60 mg equivalent of virgin methylphenidate hydrochloride, and a more preferred dosage range for the ondansetron dosage form is 4 to 16 mg equivalent of virgin ondansetron hydrochloride. Any fixed-dose permutation of methylphenidate and ondansetron within the preferred equivalent dosage ranges can be embodied within a single dosage form.

[0105] 13. When stereoisomers of the selected component 1 are present, any stereoisomer alone or combinations thereof in optimized ratios of each can be used in combination therapy embodiments. Esmirtazapine, the S(+) stereoisomer of the antidepressant Mirtazapine (e.g., Remeron®), as component 2 in dosage forms for the treatment of LID is one example of the preferred use of a stereoisomer over others.

[0106] 13.1. Mirtazapine is a tetracyclic, piperazino-azepipne compound (1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c]benzazepine; C17H19N3; molecular weight: 265.36), a so-called noradrenergic / specific serotonergic antidepressant. Commonly available mirtazapine formulations (e.g., ReMeron(R)) are marketed as a 50:50 racemic mixture of the S(+) and R(-) enantiomers.

[0107] 13.2. The drug has high affinity for 5-HT2A and 5-HT2C receptors as well as for 5-HT3, adrenergic α2 and histamine H1 receptors. Furthermore, even though the drug has the lowest affinity for 5-HT1A receptors, the drug can also enhance 5-HT1A-dependent neurotransmission through blockade of α2 adrenergic auto- and heteroreceptors and the subsequent indirect increase in serotonin release. Since the drug is a 5-HT2 and 5-HT3 receptor antagonist, 5-HT1A-mediated serotonergic transmission is preferentially enhanced (functional 5-HT1A agonist).

[0108] 13.3.Compared to the R(-) enantiomer, esmirtazapine (1) exhibits high affinity for 5-HT2A and 5-HT2C (and α2 adrenergic) receptors; (2) can be absorbed more quickly (but not too excessively) through an "enantioselective" transport process in the intestinal wall; and (3) can accumulate much more in the brain. These findings suggest that relatively lower oral doses of component 2 may be effective in combination therapy for LID. Furthermore, esmirtazapine has a shorter terminal elimination half-life (t1 / 2, about 50%) compared to the R(-) enantiomer. Therefore, it is believed that esmirtazapine is associated with a lower incidence of adverse side effects, such as excessive daytime sleepiness, compared to racemic miratazapine (e.g., ReMeron(R)) or the R(-) enantiomer.

[0109] 13.4. Esmirtazapine is primarily metabolized by CYP2D6, which displays a clinically meaningful genetic polymorphism. Thus, clearance is two-fold lower from poor metabolizers than from extensive metabolizers. Thus, while any dose of esmirtazapine can be embodied in a single combination therapy dosage form, the determination of the CYP2D6 phenotype in an individual patient prior to initiation of the combination therapy can allow for the selection of a pharmacogenetically preferred esmirtazapine dose for each individual patient ("personalized drug").

[0110] [Mode for carrying out the invention] Example 1: [MPh-IR+Ond-PR2]: Phase 2A clinical trial safety / efficacy proof of concept

[0111] Ond-PR2 is a bid dosage form made from ondansetron as active pharmaceutical ingredient (API). MPh-IR is an immediate-release generic dosage form of methylphenidate. [MPh-IR+Ond-PR2] is a single encapsulated dosage form consisting of MPh-IR and Ond-PR2 as components 1 and 2, respectively. Following in vitro dissolution testing and PK and safety evaluation in normal healthy volunteers (Ph-1), the inventors conducted a proof-of-concept, randomized, double-blind, gastric drug-controlled Phase 2A safety / efficacy clinical trial. A total of 48 patients who met the DSM-4 criteria for primary psychostimulant abuse while residing through a residential program were searched, and 30 eligible subjects were randomly divided into two groups: [MPh-IR+Ond-PR2] or gastric drug treatment group.

[0112] A single capsule containing either [MPh-IR+Ond-PR2] or dextrose (a stomach medicine) was administered once daily for 14 days. Subjects also underwent a single fMRI-based assessment 1-7 days before the first test dose (pre-treatment) and also 3-7 days after the last dose (i.e., post-treatment assessment was performed after complete washout). Established resting-state, cue-reactivity, and Go / noGO task paradigm behavioral rating scales and blood-oxygenation-level-dependent (BOLD) functional imaging results were measured with group comparisons.

[0113] Twenty-eight subjects completed 2-week drug treatment and pre- and post-treatment fMRI assessments.

[0114] [MPh-IR+Ond-PR2]PK analysis

[0115] On days 1 and 14, (1) PK parameters of the two components (i.e., MPh-IR and Ond-PR2) were measured by quantifying serum methylphenidate and ondansetron concentrations; (2) 24-hour blood PK samples were collected after a single oral dose of [MPh-IR+Ond-PR2] capsule to determine if there were any changes in these parameters after 14 days of once-daily dosing. Technical statistics for blood methylphenidate (MPh-IR) and ondansetron (Ond-PR2) concentrations at each time point were summarized as mean, standard deviation, and coefficient of variation. Prediction and statistical analysis of PK parameters were performed using SAS 9.3 and BABE SolutIon.

[0116] Table 1 shows the PK parameters of methylphenidate and ondansetron after a single oral administration of [MPh-IR+Ond-PR2] combination capsule on the first and last days of treatment (Days 1 and 14, respectively). No significant changes were observed in the Cmax, CMIn, Tmax, t1 / 2, AUC(0-24), AUC(0-infinity) and Kel parameters for either methylphenidate or ondansetron between Days 1 and 14.

[0117] [Table 1]

[0118] Efficacy of [MPh-IR+Ond-PR2] in patients with PUD

[0119] All pre-treatment and post-treatment behavioral levels and fMRI data were first converted to post-pre differences scores. The resulting post-pre scores for the gastric medication and MPh-IR+Ond-PR2 groups were compared using one-way analyses of covariance (ANCOVA) with withdrawal duration (3.0 to 12 months) for individual subjects as a covariate (p ≤ 0.05). The data presented are selected and examples provided.

[0120] Self-reported craving scores after exposure to psychostimulant-associated visual signals. In the clinical phase 2A for [MPh-IR+Ond-PR2], subjects provided scores for craving levels while performing a signal-reactivity task in a neuroimaging scanner. We assessed the change in craving levels (post-treatment minus pre-treatment) for each treatment group. ANCOVA (abstinence duration as a covariate) shows that 14 days of [MPh-IR+Ond-PR2] treatment significantly reduced self-reported craving levels in the neuroimaging scanner (Table 2).

[0121] [Table 2]

[0122] In Table 2, prob. > |t| means the probability of obtaining the predicted value of mean group variability (e.g., -1.63 for cocaine signal reactivity) when the actual difference is 0. For cocaine craving scores, there is about a 3.3% chance that the combination treatment and gastric treatment groups have equal mean scores (i.e., no variability). The 95% CI (95% confidence interval) means that we are 95% confident that the true population inverval between the combination treatment and gastric treatment patient populations falls between the lower and higher numbers (e.g., -3.12 to -0.14 for cocaine craving scores). A confidence interval that does not include 0 declares meaningful variability between treatments with 95% confidence. On the other hand, the mean variability (eg, −1.63 for cocaine craving score) is simply the mean variability between combination-treated and gastric medication-treated patients in the inventors' single experiment (ie, n=24).

[0123] Shiffman-Jarvik Subscale Scores. The majority of patients with PUD use tobacco products, regardless of whether they also have a comorbid diagnosis of tobacco use disorder. The Shiffman-Jarvik Withdrawal Scale (SJWS) is one of the psychological tests used to assess nicotine withdrawal symptoms (see Shiffman-Jarvik, 1976). A short version of the SJWS (McClernon et al., 2005) was administered to patients with PUD during the pre-treatment and post-treatment neuroimaging assessment periods. ANCOVA (abstinence duration as a covariate) shows that 14 days of [MPh-IR+Ond-PR2] treatment significantly reduced scores on the SJS craving and negative affect subscales from patients diagnosed with PUD (Table 2).

[0124] Example 2. Reversal of levodopa-induced abnormal involutary movement (LIAIM) by pergolide / ketanserin treatment

[0125] To prove that the agonist / antagonist combination therapy proposed in the present invention can effectively reverse LID and restore levodopa efficacy, an animal model experiment of LID was carried out using the combination of the DA agonist pergolide and the 5-HT2A / 2C antagonist ketanserin. In this experiment, a significant reduction in levodopa-induced abnormal involuntary movements (LIAIM) was confirmed in the LID animal model rats by the combination therapy (Figure 3).

[0126] The animal model used in this experiment was prepared as follows. First, a single injection of the dopamine neurotoxin 6-hydroxydopamine (6-OHDA) into the right medial forebrain bundle of Rhett rats was used to induce unilateral lesions of the nigrostriatal DA pathway. Three weeks after the 6-OHDA treatment, the rats were administered levodopa methyl ester (6.5 mg / kg intraperitoneally, immediately before benserazide, 25 mg / kg) twice daily for three weeks to induce levodopa-induced abnormal involuntary movement (LIAIM). The LIAIM level of the experimental animals was evaluated by measuring the LIAIM score twice a week for three hours during levodopa administration using the standard LIAIM level scale. After constructing the LIAIM, animals with severe LIAIM scores exceeding 25 and connected limbs and body axis were selected, and these animals were administered one of three treatments for two weeks: (1) pergolide (0.1mg / kg) 3.5 hours later, 5-HT2A / 2C antagonist ketanserin (1mg / kg) [L_PK group]; (2) pergolide + saline 3.5 hours later [L_PS group]; and (3) DMSO (1% in saline) + saline 3.5 hours later [L_SS group]. All drugs were administered by subcutaneous injection.

[0127] Two days after the last L_PK, L_PS or L_SS administration, all animals were administered 25 mg / kg levodopa and the LIAIM scores were measured again. A significant reversal treatment effect was found for the total LIAIM score, expressed as the percentage between the reversal treatment-after and reversal treatment-before scores (F(2,23)=8.841, p < 0.001, one-way ANOVA; Fig. 2, left panel); post-hoc Newman-Keul's test showed that combined pergolide / ketanserin treatment (L_P / K) significantly reduced LIAIM compared to L_SS or L_PS treatment (p < 0.05). No differences were observed between the latter two groups. The right panel shows the pre-time course, which indicates that L_P / K reduced the maximum LIAIM score as well as earlier LIAIM termination. [Industrial Applicability]

[0128] The present invention can be utilized in the pharmaceutical industry and related industries as well as in the manufacture of compositions for the combination treatment of neuropsychiatric disorders.

Claims

1. a) component 1 comprising methylphenidate or a pharma- ceutically acceptable salt thereof; b) a component 2 comprising ondansetron or a pharma- ceutical acceptable salt thereof; and said component 1 dissolves at least about 80% within about 1 hour, or at least about 90% within about 2 hours under dissolution test conditions in a gastric or intestinal tube; said component 2 dissolves less than about 10% within about 3 hours and more than about 80% within about 7 hours under dissolution test conditions in a gastric or intestinal tube; The pharmacologically active form of component 1 has a plasma or serum concentration Tmax of Tmax1, and the pharmacologically active form of component 2 has a plasma or serum concentration Tmax of Tmax2; the difference between the Tmax1 and the Tmax2 in the human body is in the range of 2 to 7 hours; said composition is in a unitary dosage form comprising said component 1, said component 2 and a pharma- ceutically acceptable excipient, carrier or other pharma- ceutically acceptable additive; The pharmaceutical composition, wherein the neuropsychiatric disorder is alcohol use disorder.

2. 2. The composition of claim 1, wherein the pharmacologically active form of component 1 has an elimination half-life in the human body of 5 hours or less.

3. 2. The composition of claim 1, wherein the pharmacologically active form of component 2 has an elimination half-life in the human body of not less than 3 hours and not more than 13 hours.

4. 2. The composition of claim 1, wherein the fixed combination dosage form comprises methylphenidate in a dosage equivalent to 5 mg to 80 mg of methylphenidate hydrochloride and ondansetron in a dosage equivalent to 4 mg to 16 mg of ondansetron hydrochloride.

Citation Information

Patent Citations

  • Selective serotonin 2a / 2c receptor inverse agonists as therapeutic agents for neurodegenerative diseases

    JP2006516284A